Our data suggested that pharmacological inhibition (ML364) and depletion of USP2 sensitizes TRAIL-mediated apoptosis in metastatic ccRCC (Caki-1 cells) and metastatic pRCC (ACHN cells) (Figure 4A and Figure 6A). Here, USP2 is linked to nonpapillary renal cell carcinoma.